Aphria Inc. Is Uglifying Itself With Absurdly Expensive Acquisitions

Aphria Inc. (TSX:APH) may be shooting itself in the foot with these recent acquisitions.

| More on:
caution

The cannabis market in general is a very dangerous place to be right now. Last year, pot stocks were driven by political developments, supply deals, and partnerships with foreign firms, but now pot stocks are being propelled higher by M&A activity, as the bigger producers look to consolidate the industry to prepare for years of what many believe is overwhelming demand for legal cannabis.

There are still a tonne of unforeseen obstacles that could stand in the way of Canada’s top cannabis producers, and at current valuations, I’d advise investors take a rain-check and come back after a 50-60% correction, which I think is extremely probable this year.

Aphria Inc. (TSX:APH) is my least favourite Canadian cannabis stock for many reasons. Despite possessing the most efficient operations and the best fundamentals in its industry, there are a lot of other insidious traits that I believe will haunt investors who fail to look past the “incredible fundamentals” at the very early stages of an emerging industry.

First, Aphria has U.S. assets, which could affect its ability to trade on the TSX. That is, of course, until the company decides to dispose of its U.S. assets before some unknown deadline, which may or may not exist at this point in time.

What are the implications of a delisting?

Nobody knows, but CEO Vic Neufeld has downplayed the matter, which I think is a cause for concern, especially since he may be putting investors at risk from the severe lack of transparency. At this point, Neufeld may be favouring the divestment of the U.S. assets; however, I think it’ll be a tough sell, especially given Aphria’s vulnerable position. It’s clear that the buyer will have most, if not all, of the bargaining power should a deal be made, and that’s bad news for Aphria shareholders.

Fellow Fool contributor Will Ashworth noted that Aphria may be better off ditching the TSX for an alternative exchange like Canadian Securities Exchange, where there are ample marijuana firms. This may be a better move, but I doubt this is will be the route it’ll end up taking.

Second, Aphria has been wheeling and dealing a lot lately at a time when many analysts and Fools, including me, believe that the entire cannabis market is in a bubble. In a previous piece, I mentioned my distaste for Aphria’s Broken Coast acquisition for $230 million, and Nuuvera Inc. was scooped up just a few weeks later for $826 million.

Nuuvera is a great grower that provides Aphria exposure to Europe, Africa, and the Middle East, but the 21% premium that was paid makes me cringe, and it brings back memories of Valeant Pharmaceuticals Intl Inc. and its greed-fueled acquisition spree.

The recent deal makes it look like Aphria is making moves to “keep up with the Joneses,” where Aurora Cannabis Inc. (TSX:ACB) is Mr. and Mrs. Jones. Aphria’s Nuuvera deal was announced just days after Aurora’s $1.1 billion acquisition of CanniMed Therapeutics Inc.

Clearly, the market is valuing these smaller cannabis firms ridiculously high, but I suspect they won’t be worth nearly as much as we head into the latter part of the year. Aurora’s CanniMed deal severely dilute shareholders, and I fear this could be just the start of further deals that will dilute shareholders to death.

Bottom line

There are a tonne of differences between Aurora and Aphria versus Valeant (like differing debt levels). But one thing they have in common is the trigger-happy nature of acquisitions, which could be coming at a fast and furious rate over the next few months. I personally believe such deals may be sacrificing long-term shareholder value in favour of shorter-term results.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

ETF chart stocks
Investing

Here Are My 2 Favourite ETFs for 2025

These are the ETFs I'll be eyeballing in the New Year.

Read more »

money goes up and down in balance
Dividend Stocks

This 6% Dividend Stock Is My Top Pick for Immediate Income

This Canadian stock has resilient business model, solid dividend payment and growth history, and a well-protected yield of over 6%.

Read more »

Canadian energy stocks are rising with oil prices
Energy Stocks

Outlook for Cenovus Energy Stock in 2025

A large-cap energy stock and TSX30 winner is a screaming buy for its bright business outlook and visible growth potential.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Stock Market

CRA: Here’s the TFSA Contribution Limit for 2025

The TFSA is a tax-sheltered account that allows you to hold diversified asset classes at a low cost.

Read more »

Hourglass and stock price chart
Tech Stocks

1 Canadian Stock Ready to Surge Into 2025

There is a lot of uncertainty about the market in general as we move closer to the following year, but…

Read more »

think thought consider
Stock Market

Billionaires Are Selling Apple Stock and Picking up This TSX Stock Instead

Billionaires like Warren Buffett continue to trim stakes in Apple stock, with others picking up this long-term stock instead.

Read more »

ways to boost income
Dividend Stocks

1 Excellent TSX Dividend Stock, Down 25%, to Buy and Hold for the Long Term

Down 25% from all-time highs, Tourmaline Oil is a TSX dividend stock that offers you a tasty yield of 5%…

Read more »

canadian energy oil
Energy Stocks

Is Baytex Energy Stock a Good Buy?

Baytex just hit a 12-month low. Is the stock now oversold?

Read more »